Express Scripts to Revamp Practices to Resolve FTC Action Alleging Inflated Insulin Prices
- February 06, 2026
The Cigna Group’s Express Scripts, Inc. will overhaul its business practices under a proposed consent order to resolve a Federal Trade Commission (FTC) action alleging the pharmacy benefit manager (PBM) engaged in unfair trade practices by prioritizing high rebates from drug manufacturers for favorable formulary placement causing artificially inflated insulin list prices that shifted higher costs to vulnerable patients, the FTC announced February 4.
ARTICLE TAGS
You must be logged in to access this content.